ZAI Lab Begins Trial of Novel Respiratory Disease Drug

ZAI Lab of Shanghai has dosed the first subject in a Phase 1 study of ZL-2102, a novel anti-inflammatory drug, as a treatment for chronic respiratory diseases. The trial is being conducted in Australia among healthy volunteers. ZAI Lab in-licensed global rights to two novel compounds from Sanofi last year, both of which are potential treatments for respiratory diseases (see story). At the time, the drugs had already completed their pre-clinical development. ZL-2102 is the first to begin a clinical trial. More details.... Stock Symbol: (NYSE: SNY) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.